A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

NCT07206225 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

294

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-muscle Invasive Bladder Cancer

Interventions

DRUG: PF-08052667
DRUG: Sasanlimab
DRUG: BCG
DRUG: PF-02921367

Sponsor

Pfizer